Booya. We’re up 143% With Ardelyx (ARDX) in Three Months – and That Ain’t...
Ardelyx Adds 16% to $3.82 as Wedbush Upgrades After Q4 Earnings.
Ardelyx ( NASDAQ: ARDX ) gained 35%...
SILO Pharma (SILO) Gains 53%
For Now, Volatility Remains and the Traders, Seem to be Having the Most Fun.
Silo Pharma Gains 53%...
He Shoots And He Scores. Ardelyx (ARDX) Gains 78%. Happy New Year!
Ah yes, and Gains Come to the Patient, as the FDA Moves the Ardelyx Ball Further Along.
Provention Bio (PRVB) Gains 26% Last Week.
We're up 106% From Adding to the 2022 Watch List Last July. And up 26% a Week After Urging Holders to Calm...
FDA Approval for Provention Bio (PRVB).
Re-cork the Champagne!
We were contemplating (dreaming) about an opening price over $12, and then a drift up...
Adding Ardelyx (ARDX) $1.57 to Watch List.
FDA Advisory Committee Says Go Forth Young Man!
While we hadn't previously owned Ardelyx, nor are they a...
Provention Biosciences (PRVB) Enters the Danger Zone.
Chart Looks Beautiful - But Nervous is why, we use soft and dry.
LIVE QUOTE
We'll...
Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
Revive (RVVTF) Hits a Snag?
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
First our summary."FDA provided communication that...
Revive Therapeutics (RVVTF) Annual Shareholder Meeting.
ANNUAL SHAREHOLDER MEETING
https://vimeo.com/752050831